Artiva Biotherapeutics, Inc. $ARTV Shares Sold by venBio Partners LLC

Key Points

• venBio Partners LLC has reduced its stake in Artiva Biotherapeutics by 21.1%, now owning approximately 4.92% of the company, after selling 320,996 shares.
• Artiva Biotherapeutics recently reported a quarterly loss of ($0.87) earnings per share, missing analysts' expectations, and is projected to have a total earnings per share of -4.95 for the current fiscal year.
• The company received a "buy" rating from HC Wainwright with a price objective of $12.00, while other analysts have set a consensus price target of $17.00.

venBio Partners LLC reduced its stake in shares of Artiva Biotherapeutics, Inc. (NASDAQ:ARTV - Free Report) by 21.1% in the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 1,198,975 shares of the company's stock after selling 320,996 shares during the quarter. Artiva Biotherapeutics makes up approximately 2.9% of venBio Partners LLC's portfolio, making the stock its 7th largest position. venBio Partners LLC owned about 4.92% of Artiva Biotherapeutics worth $3,597,000 as of its most recent SEC filing.

Several other large investors have also made changes to their positions in ARTV. Wells Fargo & Company MN grew its position in shares of Artiva Biotherapeutics by 64.0% during the 4th quarter. Wells Fargo & Company MN now owns 8,616 shares of the company's stock worth $87,000 after buying an additional 3,361 shares during the period. BNP Paribas Financial Markets raised its position in shares of Artiva Biotherapeutics by 262.1% during the 4th quarter. BNP Paribas Financial Markets now owns 9,879 shares of the company's stock valued at $100,000 after acquiring an additional 7,151 shares during the last quarter. Nuveen LLC bought a new stake in shares of Artiva Biotherapeutics during the 1st quarter valued at $144,000. Charles Schwab Investment Management Inc. lifted its stake in shares of Artiva Biotherapeutics by 26.1% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 54,881 shares of the company's stock valued at $165,000 after purchasing an additional 11,355 shares during the period. Finally, Deutsche Bank AG bought a new position in shares of Artiva Biotherapeutics in the 4th quarter worth $216,000.

Artiva Biotherapeutics Trading Down 0.3%

Shares of Artiva Biotherapeutics stock opened at $3.15 on Friday. The business's 50-day moving average price is $2.47 and its 200-day moving average price is $2.77. Artiva Biotherapeutics, Inc. has a 12 month low of $1.47 and a 12 month high of $17.31.

Artiva Biotherapeutics (NASDAQ:ARTV - Get Free Report) last issued its quarterly earnings data on Wednesday, August 6th. The company reported ($0.87) earnings per share for the quarter, missing analysts' consensus estimates of ($0.84) by ($0.03). As a group, sell-side analysts anticipate that Artiva Biotherapeutics, Inc. will post -4.95 earnings per share for the current fiscal year.

Insider Activity at Artiva Biotherapeutics

In other news, CEO Fred Aslan sold 25,500 shares of the business's stock in a transaction dated Friday, August 15th. The stock was sold at an average price of $2.73, for a total value of $69,615.00. Following the transaction, the chief executive officer directly owned 386,693 shares in the company, valued at $1,055,671.89. The trade was a 6.19% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 21.40% of the stock is owned by insiders.

Wall Street Analyst Weigh In

A number of analysts have recently commented on ARTV shares. HC Wainwright upgraded shares of Artiva Biotherapeutics to a "buy" rating and set a $12.00 price objective on the stock in a report on Wednesday, June 11th. Needham & Company LLC decreased their price target on Artiva Biotherapeutics from $23.00 to $18.00 and set a "buy" rating on the stock in a research report on Thursday, May 15th. Four investment analysts have rated the stock with a Buy rating, According to MarketBeat, Artiva Biotherapeutics presently has a consensus rating of "Buy" and a consensus price target of $17.00.

About Artiva Biotherapeutics

Artiva Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.